Cancer Antigen 15-3 (CA-15-3)

Swiss-Prot Accession Number:


 
Therapy Indications
 
Myriad RBM Publications Publications
TGFb receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer (2019) Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplangue G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J Cancer Chemotherapy and Pharmacology
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in (2018) Savona M, Pollyea D, Stock W, Oehler V, Schroeder MA, Lancet J, McCloskey J, Kantarigian H, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE Clinical Cancer Research
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports